Internal Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Oliver JM et al. – Omalizumab may reduce asthma symptoms in part by suppressing the FcRI–mediated production by basophils of Th2 cytokines and selected chemokines. Anti–IgE–stimulated basophil cytokine synthesis appears more sensitive than histamine release to the loss of FcRI caused by omalizumab treatment.


   

Today in Allergy/Immunology...keeping you current

Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09

Solar urticaria
Allergy and Asthma Proceedings, 10/12/09

The definition and diagnostic testing of physical and cholinergic urticarias - EAACI/GA2LEN/EDF/UNEV consensus panel recommendations
Allergy, 11/16/09

Today in Clinical Pharmacology...keeping you current

Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09

New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09

Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09

Today in Pulmonology...keeping you current

An Umbrella Review: Corticosteroid Therapy for Adults with Acute Asthma
American Journal of Medicine, 10/27/09

Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism
Osteoporosis International, 10/30/09

Magnesium sulphate in the treatment of acute asthma: evaluation of current practice in adult emergency departments
Emergency Medicine Journal, 10/27/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address